NetworkNewsBreaks – VistaGen Therapeutics (NASDA
Post# of 130
(Total Views: 245)
Posted On: 10/01/2020 3:21:36 PM
NetworkNewsBreaks – VistaGen Therapeutics (NASDAQ: VTGN) CEO Discusses ‘Sea of Change’ to Future of Anxiety Treatment
VistaGen Therapeutics’ (NASDAQ: VTGN) CEO Shawn Singh authored a recent article for Life Science Leader titled, “The Future of Anxiety Treatment Will Be Drastically Different.” In the piece, Singh, an experienced professional who has dedicated over 25 years to biopharma and medical device industries, addresses the current standard of care for anxiety disorders and its inability to meet the growing need. “As researchers learn more about psychological therapy for anxiety disorders and medication options to complement it, efforts are underway to develop innovative medications to displace current anti-anxiety drugs that are not effective for all patients and are associated with significant potential side effects and safety concerns, especially benzodiazepines,” Singh writes. “If these new generation alternatives are developed successfully in adequate and well-controlled clinical trials, the future of anxiety disorder treatment will look drastically different from the current standard of care, and that sea of change couldn’t come a moment too soon.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
VistaGen Therapeutics’ (NASDAQ: VTGN) CEO Shawn Singh authored a recent article for Life Science Leader titled, “The Future of Anxiety Treatment Will Be Drastically Different.” In the piece, Singh, an experienced professional who has dedicated over 25 years to biopharma and medical device industries, addresses the current standard of care for anxiety disorders and its inability to meet the growing need. “As researchers learn more about psychological therapy for anxiety disorders and medication options to complement it, efforts are underway to develop innovative medications to displace current anti-anxiety drugs that are not effective for all patients and are associated with significant potential side effects and safety concerns, especially benzodiazepines,” Singh writes. “If these new generation alternatives are developed successfully in adequate and well-controlled clinical trials, the future of anxiety disorder treatment will look drastically different from the current standard of care, and that sea of change couldn’t come a moment too soon.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)VistaGen Therapeutics, Inc. (VTGN) Stock Research Links
Scroll down for more posts ▼